Open Internet by MindsNet

Addressing Unmet Medical Needs in Clinical Trials

The current clinical development landscape is dominated by me-too and best-in-class molecules for validated targets, leaving unmet needs in areas such as pediatric cancers and non-genetically driven cancers. This raises questions about the root causes of this issue, including the lack of good science, translation of risky biology, risk-averse funding, or big pharma's wait-and-see approach. There is a need to identify and address these bottlenecks to bring innovation to underserved patient populations.

Science, Medicine, Pharmacology